Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 103, 381-388
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019The Journal of Infectious Diseases, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, ChinaNew England Journal of Medicine, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)International Journal of Infectious Diseases, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studiesBMJ, 2015
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology and Infection, 2004